U-Shape Association Between Hemoglobin A1c and Late Mortality in Patients With Heart Failure After Cardiac Surgery

被引:17
作者
Engoren, Milo [1 ,2 ]
Schwann, Thomas A. [3 ]
Arslanian-Engoren, Cynthia [4 ]
Maile, Michael [1 ]
Habib, Robert H. [5 ,6 ]
机构
[1] Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA
[2] Mercy St Vincent Med Ctr, Dept Anesthesiol, Toledo, OH USA
[3] Univ Toledo, Dept Surg, Toledo, OH 43606 USA
[4] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA
[5] Amer Univ Beirut, Dept Internal Med, Beirut, Lebanon
[6] Amer Univ Beirut, Outcomes Res Unit, Beirut, Lebanon
关键词
INCREASE;
D O I
10.1016/j.amjcard.2012.12.054
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hemoglobin A1c (HbA1c) levels are used as a measure of glycemic control, with greater levels indicating poorer control and a greater risk of death. However, recent studies have found a U-shaped association between the HbA1c levels and mortality in patients with heart failure, with the lowest risk of death associated with elevated HbA1c levels, usually >7%. Cardiac surgery is frequently used to mitigate the signs and symptoms of heart failure. The purpose of the present study was to determine the association between HbA1c levels and late mortality in cardiac surgery patients with and without heart failure. Patients with and without New York Heart Association class III or IV heart failure were divided into quartiles according to the preoperative HbA1c level. Mortality was determined for each group and compared using chi-square tests and Cox modeling. Of the 311 patients with heart failure, 65 (21%) were dead at follow-up compared to 57 of 669 patients (9%) without heart failure (p <0.001). After adjusting for confounders, the patients without heart failure and with HbA1c <= 5.7% had the lowest risk of death. In patients with preoperative heart failure, we found a U-shaped association between HbA1c levels and late mortality, with those patients with HbA1c levels of 5.8% to 6.2% having the lowest risk of death. HbA1c levels <= 5.7% and >= 7.2% were associated with statistically significant greater risks of death. In conclusion, we found in patients with heart failure that the lowest risk of death was associated with HbA1c levels of 5.8% to 6.2%. (C) 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:1209-1213)
引用
收藏
页码:1209 / 1213
页数:5
相关论文
共 12 条
[1]   Relationship of Hemoglobin A1C and Mortality in Heart Failure Patients With Diabetes [J].
Aguilar, David ;
Bozkurt, Biykem ;
Ramasubbu, Kumudha ;
Deswal, Anita .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (05) :422-428
[2]   'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas [J].
Bilinska, Maria ;
Potocka, Joanna ;
Korzeniowska-Kubacka, Iwona ;
Piotrowicz, Ryszard .
CORONARY ARTERY DISEASE, 2007, 18 (06) :455-462
[3]   The prevalence of elevated hemoglobin A1c in patients undergoing coronary artery bypass surgery [J].
Engoren, Milo ;
Habib, Robert H. ;
Zacharias, Anoar ;
Schwann, Thomas A. ;
Riordan, Christopher J. ;
Durham, Samuel J. ;
Shah, Aamir .
JOURNAL OF CARDIOTHORACIC SURGERY, 2008, 3 (1)
[4]   An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure -: art. no. e1-91.e6 [J].
Eshaghian, S ;
Horwich, TB ;
Fonarow, GC .
AMERICAN HEART JOURNAL, 2006, 151 (01) :91.e1-91.e6
[5]   Risk of Death and Cardiovascular Outcomes with Thiazolidinediones: A Study with the General Practice Research Database and Secondary Care Data [J].
Gallagher, Arlene M. ;
Smeeth, Liam ;
Seabroke, Suzie ;
Leufkens, Hubert G. M. ;
van Staa, Tjeerd P. .
PLOS ONE, 2011, 6 (12)
[6]   Reverse Epidemiology in Systolic and Nonsystolic Heart Failure Cumulative Prognostic Benefit of Classical Cardiovascular Risk Factors [J].
Gueder, Guelmisal ;
Frantz, Stefan ;
Bauersachs, Johann ;
Allolio, Bruno ;
Wanner, Christoph ;
Koller, Michael T. ;
Ertl, Georg ;
Angermann, Christiane E. ;
Stoerk, Stefan .
CIRCULATION-HEART FAILURE, 2009, 2 (06) :563-571
[7]   EVALUATING THE YIELD OF MEDICAL TESTS [J].
HARRELL, FE ;
CALIFF, RM ;
PRYOR, DB ;
LEE, KL ;
ROSATI, RA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1982, 247 (18) :2543-2546
[8]  
Nieto FJ, 1996, AM J EPIDEMIOL, V143, P1059
[9]   Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis [J].
Pantalone, K. M. ;
Kattan, M. W. ;
Yu, C. ;
Wells, B. J. ;
Arrigain, S. ;
Jain, A. ;
Atreja, A. ;
Zimmerman, R. S. .
DIABETES OBESITY & METABOLISM, 2012, 14 (09) :803-809
[10]   Overall C as a measure of discrimination in survival analysis:: model specific population value and confidence interval estimation [J].
Pencina, MJ ;
D'Agostino, RB .
STATISTICS IN MEDICINE, 2004, 23 (13) :2109-2123